Research Paper Volume 13, Issue 7 pp 10450—10467

RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma


Figure 5. The difference in estimated immune cell fraction. Distribution plot of estimated immune cell fraction among between RIPK2 high- and low- expression samples. Statistical significance was determined by the Wilcoxon rank-sum test.